- Home
- GECC vs AGEN Comparison
GECC vs AGEN Comparison
Compare GECC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- AGEN
- Stock Information
- Founded
- GECC 2016
- AGEN 1994
- Country
- GECC United States
- AGEN United States
- Employees
- GECC N/A
- AGEN N/A
- Industry
- GECC Finance: Consumer Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GECC Finance
- AGEN Health Care
- Exchange
- GECC Nasdaq
- AGEN Nasdaq
- Market Cap
- GECC 123.1M
- AGEN 87.7M
- IPO Year
- GECC N/A
- AGEN 2000
- Fundamental
- Price
- GECC $10.96
- AGEN $6.69
- Analyst Decision
- GECC
- AGEN Buy
- Analyst Count
- GECC 0
- AGEN 4
- Target Price
- GECC N/A
- AGEN $13.00
- AVG Volume (30 Days)
- GECC 27.3K
- AGEN 1.4M
- Earning Date
- GECC 07-31-2025
- AGEN 08-07-2025
- Dividend Yield
- GECC 13.96%
- AGEN N/A
- EPS Growth
- GECC N/A
- AGEN N/A
- EPS
- GECC 0.42
- AGEN N/A
- Revenue
- GECC $42,909,000.00
- AGEN $99,524,000.00
- Revenue This Year
- GECC $32.54
- AGEN $12.69
- Revenue Next Year
- GECC N/A
- AGEN N/A
- P/E Ratio
- GECC $25.94
- AGEN N/A
- Revenue Growth
- GECC 18.13
- AGEN N/A
- 52 Week Low
- GECC $8.87
- AGEN $1.38
- 52 Week High
- GECC $11.39
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- GECC 58.40
- AGEN 63.27
- Support Level
- GECC $10.83
- AGEN $4.78
- Resistance Level
- GECC $10.98
- AGEN $7.34
- Average True Range (ATR)
- GECC 0.17
- AGEN 0.64
- MACD
- GECC 0.02
- AGEN 0.13
- Stochastic Oscillator
- GECC 97.13
- AGEN 75.33
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).